Financial Snapshot
What does The Cooper Companies, Inc. latest financial snapshot show?
Mixed-to-Strong. The strongest factor is profitable organic growth, while the main concern is leverage plus litigation-adjusted GAAP loss.
The latest verified fiscal period is Q2 2026, and this snapshot blends growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. For a broader ownership context, see Exploring The Cooper Companies, Inc. (COO) Investor Profile: Who's Buying and Why?
Net debt deserves deeper analysis first because it most directly affects financing capacity, interest burden, and how much room The Cooper Companies has to keep investing while handling $209M of Q2 2026 interest expense.
Revenue and earnings quality
Does Cooper Companies, Inc.'s revenue growth convert into quality earnings?
Mixed. Cooper Companies, Inc. is still growing, and FY2025 showed the clearest quality signal because $39B revenue rose 80% with 80% organic growth, but Q2 2026 GAAP losses and weaker organic momentum show the conversion into clean earnings is uneven.
Growth quantity is strong, but growth quality is uneven. Investors compare revenue durability with operating income, net income, and diluted EPS across compatible annual periods because revenue can rise while profits stay pressured by costs, financing, or one-time items. That is why the gap between reported growth and GAAP results matters.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $1082B, up 80% reported and 50% organically, Q2 2026 | $39B, FY2025 | Verified growth was both reported and organic, so it was not only acquisition or currency driven. | The revenue base looks repeatable, but the lower organic pace versus FY2025 suggests growth is less powerful than before. |
| Operating Income | Not provided | Not provided | Not enough data to compare operating leverage directly. | Investors cannot confirm whether margins improved as fast as revenue. |
| Net Income | $(781M) loss, Q2 2026 | Not provided | GAAP pressure is clear, and FMP 2026-04-30 shows net income growth of -15956%. | Final earnings do not yet confirm the revenue trend on a GAAP basis. |
| Diluted EPS | $121, non-GAAP diluted EPS, Q2 2026 | Not provided | Adjusted per-share growth was strong, but the GAAP side is still strained. | Shareholders see better earnings power on an adjusted basis than on reported profit. |
How durable is Cooper Companies, Inc.'s revenue?
The strongest durability signal is recurring medical device demand across CooperVision and CooperSurgical, but the biggest visibility limit is uneven regional performance, including Asia Pacific revenue down 60% in Q2 2026.
- Demand Quality: Demand looks recurring because contact lenses and fertility products tend to be repeat-purchase categories, but the pace can still vary by geography and cycle.
- Pricing and Volume: The split between price, volume, and mix is not fully provided, so the growth mix cannot be isolated precisely.
- Diversification: CooperCompanies has two main revenue streams, CooperVision and CooperSurgical, but Q2 2026 still showed regional concentration pressure, especially in Asia Pacific.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help you organize how The Cooper Companies, Inc. (COO): History, Ownership, Mission, How It Works & Makes Money turns medical-device demand into earnings quality.
That sets up the next question investors ask: how much of this growth turns into operating profit and cash conversion.
Profitability & Cash Quality
Are The Cooper Companies, Inc.'s margins and cash flow financially healthy?
Yes on adjusted profitability and cash, but not on GAAP earnings. Q2 2026 Non-GAAP operating margin improved by 260 basis points year over year, while a $2716M litigation charge pushed GAAP results into loss. Free cash flow stayed positive, so cash generation still supports reported performance better than GAAP net income does.
The gap between gross, operating, and net margin matters here. Gross margin shows product economics under tariff and freight pressure; operating margin shows how well restructuring savings and AI-enabled workflow automation offset spending; net margin reflects the impact of interest, tax, and the litigation charge. The Cooper Companies, Inc.'s Mission Statement, Vision, & Core Values (2026) of The Cooper Companies, Inc. (COO) also helps frame whether efficiency gains are aligned with longer-term operating discipline.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | Q2 2026: not separately provided | Prior year: not separately provided | Tariff and freight pressure on costs | Product economics are facing input-cost headwinds. |
| Operating Margin | Q2 2026 Non-GAAP Operating Margin: 275% | Up 260 basis points from prior year | Restructuring savings and AI-enabled workflow automation | Scale and efficiency appear to be improving adjusted operating leverage. |
| Net Margin | Q2 2026 GAAP net margin: not cleanly representative | Prior year: not provided | $2716M litigation charge, plus $209M interest expense and 154% effective tax rate | GAAP profitability is depressed and does not reflect routine operations well. |
| Operating Cash Flow | 2026-04-30: unavailable | Previous compatible value unavailable | FMP shows operating cash flow growth of -19502%, but no operating cash flow amount was supplied | Cash conversion cannot be confirmed from the provided operating cash flow figure. |
| Free Cash Flow | Q2 2026: $964M | Previous supplied value unavailable | Capital expenditures were $864M, leaving positive cash after reinvestment | There is still room for reinvestment, debt service, and other capital uses. |
What most affects The Cooper Companies, Inc.'s cash conversion?
Positive free cash flow is mainly driven by earnings that remain stronger on a non-GAAP basis than on GAAP, while the biggest constraint is reinvestment through $864M of capital expenditures. That looks partly structural because the business still needs ongoing investment.
- Main Driver: Restructuring savings and AI-enabled workflow automation are supporting cash conversion; the effect looks structural, not one-off.
- Evidence Gap: The supplied data do not separate working-capital changes or show operating cash flow in dollar terms.
- Metric to Monitor: Track operating cash flow and gross margin next.
Debt and Liquidity
Can The Cooper Companies support its debt and liquidity needs?
Mixed. The Cooper Companies has enough protection from strong cash generation, but its $23B net debt and $209M quarterly interest expense keep leverage and debt service as the main concern. Liquidity looks manageable only if free cash flow and adjusted earnings stay strong.
The balance sheet can’t be judged by cash alone. The Cooper Companies also needs enough operating earnings, asset quality, and refinancing flexibility to cover debt service, preserve solvency, and keep funding investment. In this case, recurring free cash flow is the key support, while leverage remains the pressure point.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | Cash and cash equivalents of $13880M; Q2 2026 free cash flow of $964M; FY 2026 free cash flow guidance of approximately $650M excluding litigation payouts. | Mixed | Near-term obligations look supportable, but working-capital detail is not provided here, so liquidity depends heavily on ongoing cash generation. |
| Total and Net Debt | Net debt of $23B at April 30, 2026; total debt is also disclosed in the supplied data set. | Mixed | Leverage is meaningful and limits flexibility, so debt reduction needs strong internal cash flow. |
| Debt Service and Refinancing | Interest expense of $209M in Q2 2026, offset by strong quarterly free cash flow. | Mixed | The company can service debt from operations, but refinancing risk rises if earnings or cash flow weaken. |
| Asset Quality | Broad operating assets, medical device franchises, and segment cash generation support the capital base; no specific impairment or inventory data was supplied. | Mixed | Asset quality looks useful as a support for cash flow, but the analysis is limited without detail on receivables, inventory, or goodwill. |
| Liabilities and Equity | Latest verified liabilities and shareholders' equity were not supplied in the prompt. | Mixed | Obligation coverage cannot be fully measured here, so investors should track whether equity and retained cash flow keep absorbing debt pressure. |
What balance-sheet risk matters most for The Cooper Companies?
Debt load is the main risk. The company’s $23B net debt matters more than liquidity today because the business must keep producing strong free cash flow to protect debt service and preserve flexibility.
- Current Exposure: Net debt is $23B and Q2 2026 interest expense was $209M.
- Protection: Q2 2026 free cash flow of $964M and FY 2026 guidance of approximately $650M excluding litigation payouts.
- Warning Signal: Watch for weaker adjusted earnings or free cash flow, since that would tighten leverage capacity fast.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Exploring The Cooper Companies, Inc. (COO) Investor Profile: Who's Buying and Why? can help you organize the research into clear arguments.
Capital Discipline
Can Cooper Companies earn adequate returns while funding growth?
Capital efficiency is Mixed. $964M in Q2 2026 free cash flow after $864M of capital expenditures shows internal cash was enough for reinvestment in the latest quarter, but funding is not unconstrained because buybacks, acquisitions, debt, and litigation payouts still matter.
Return measures need leverage, asset intensity, capital expenditure, working capital, and outside funding in the picture. For Cooper Companies, the key question is not just whether cash is positive, but whether that cash can cover growth spend, balance sheet obligations, and shareholder returns without stretching financial flexibility.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable in the supplied data for this block. | Operating margins and capital efficiency cannot be tested directly here. | Invested capital may be creating value, but this cannot be confirmed from the provided figures alone. |
| ROE and ROA | Unavailable in the supplied data for this block. | Leverage and asset intensity cannot be separated cleanly without the ratios. | Shareholder return quality and asset use remain unproven from the supplied evidence. |
| Maintenance and Growth Investment | Q2 2026 free cash flow was $964M after capital expenditures of $864M; R&D increased in CooperSurgical due to project spend and pharmacovigilance fees, and decreased in CooperVision. | Spending looks targeted rather than broad-based, with growth concentrated in product and segment priorities. | Operations appear to need meaningful but manageable reinvestment to support premium daily disposable silicone hydrogel lenses, pediatric myopia management, MyDay multifocal and toric launches, and Aquaform technology. |
| Internal Funding Capacity | Internal cash flow stayed positive; Cooper Companies also repurchased $131M of stock, about 174000 shares, at an average price of $75.84, with $8608M of authorization remaining. | Reinvestment is currently internally funded, but capital allocation still competes with debt, litigation payouts, acquisitions, and buybacks. | Flexibility is decent, yet shareholder returns could tighten if obligations rise or cash generation weakens. |
Are Cooper Companies returns on capital sustainable?
Mostly yes for now, because CooperVision’s premium lens portfolio and CooperSurgical’s targeted spend support durability. Returns would weaken if higher litigation payouts, heavier acquisition funding, or softer cash generation force more external financing.
- Operating Source: Premium daily disposable silicone hydrogel lenses, MyDay launches, pediatric myopia management, and Aquaform-driven product mix support cash generation.
- Funding Requirement: The largest verified needs are $864M of capital expenditures, R&D project spend, buybacks, and acquisition obligations.
- Durability Test: Watch whether free cash flow stays above reinvestment needs and whether debt, litigation payouts, or working capital pressure start absorbing more cash.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help you organize the research into clear arguments. For deeper research, Exploring The Cooper Companies, Inc. (COO) Investor Profile: Who's Buying and Why? can help connect ownership behavior with capital discipline and strategy.
Financial Resilience
How resilient is Given Company, and which warning signs matter most?
Resilience is Mixed. The main buffer is settlement progress plus insurance recovery against the recall-related charge, but the most important verified warning sign is the $3241M litigation liability tied to the December 2023 voluntary recall.
Given Company can still fund essential investment if operating cash flow stays steady, but resilience weakens if litigation payouts, regional demand softness, or tariff and freight costs keep cash tied up. That is why the net pre-tax charge of $2716M and the Asia Pacific slowdown matter for liquidity, debt service, and flexibility.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Recall-related legal costs and weaker Asia Pacific demand can hurt operating leverage, earnings, cash flow, and debt capacity. CooperVision Asia Pacific Revenue: $1306M, down 60%. | Settlement progress, $525M insurance recovery, product portfolio rationalization, and premium product launches. | Further organic revenue decline, margin compression, or lower cash flow would confirm deterioration. |
| Working-Capital or Investment Pressure | Litigation payments, tariffs, freight, and growth spending can absorb cash that would otherwise support operations or expansion. | Internal funding capacity, restructuring completed in Q4 2025, and anticipated $50M in annual savings starting in fiscal 2026. | Weak operating cash flow, rising working capital, or heavier investment needs would be the key signal. |
| Interest or Refinancing Pressure | Higher rates would matter more if cash flow stays under pressure from the recall charge and cost inflation, reducing flexibility for debt service and refinancing. | Insurance recovery and cost savings improve near-term liquidity support. | Rising debt pressure, weaker interest coverage, or tighter liquidity would show growing strain. |
Which financial warning signs should investors monitor at Given Company?
Watch litigation cash outflows and free cash flow first, then Asia Pacific organic revenue, then tariff and freight costs. The litigation charge is confirmed deterioration; regional weakness and cost pressure are still important future risks. Exploring The Cooper Companies, Inc. (COO) Investor Profile: Who's Buying and Why?
Litigation cash burn and recall costs
The recorded $3241M liability, partially offset by $525M insurance recovery, shows the core exposure. Settlement progress helps, but investors should monitor free cash flow excluding and including litigation payouts.
Asia Pacific demand softness
CooperVision Asia Pacific Revenue: $1306M, down 60%, shows the regional risk. Japan and China softness can pressure growth, though premium launches and portfolio rationalization can help; watch organic revenue growth next.
Tariff and freight cost pressure
Full Year 2026 Tariff Expense Estimate: $22M, with potential refunds up to $15M, shows a margin headwind. Restructuring savings and AI-enabled workflow automation help, but gross margin and operating margin are the next metrics to watch.
Financial Health Scorecard
What does Cooper Companies financial health mean for investors?
Overall, the score is Mixed, with the strongest factor being adjusted profitable growth and the weakest factor being legal and leverage overhang. The most important condition for the investment case is whether durable medical device demand keeps converting into cash fast enough to cover debt and litigation pressure.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Strong | Q2 2026 revenue of $1082B was up 80% reported and 50% organically, while Q2 2026 non-GAAP diluted EPS of $121 rose 260% year-over-year. |
| Profitability and Cash | Strong | Q2 2026 non-GAAP operating margin of 275% improved by 260 basis points, and free cash flow of $964M stayed positive after capital expenditures of $864M. |
| Balance Sheet and Liquidity | Mixed | Net debt of $23B and interest expense of $209M are manageable only if cash generation stays steady, so leverage remains a real investor constraint. |
| Capital Efficiency | Mixed | Capex, R&D, acquisitions, and buybacks all compete for capital, but free cash flow guidance of approximately $650M excluding litigation payouts supports funding flexibility. |
| Financial Resilience | Mixed | Restructuring savings and automation help, but litigation, Asia Pacific softness, tariff expense, and freight pressure still create downside risk in a tougher operating environment. |
- What Supports the Thesis: Durable medical device demand, strong adjusted profit growth, and positive free cash flow support the case.
- What Challenges the Thesis: Litigation exposure and leverage keep GAAP earnings and balance sheet risk from looking clean.
- What to Monitor: Organic revenue growth, free cash flow, net debt.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help you organize the research into clear arguments. For more context on strategy, see Mission Statement, Vision, & Core Values (2026) of The Cooper Companies, Inc. (COO); forecasts and scenarios matter here because cash conversion, leverage, and litigation risk will shape any valuation path.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
How much does litigation affect Cooper's margins?
Litigation materially distorted GAAP profitability in Q2 2026 The company recorded a $2716M net pre-tax charge, contributing to a GAAP Net Income: $(781M) loss, while Q2 2026 Non-GAAP Operating Margin: 275% showed stronger adjusted operating performance
Can Cooper reduce debt using free cash flow?
Cooper has positive internal funding capacity, but debt reduction depends on cash priorities Q2 2026 Free Cash Flow: $964M supports flexibility, while Net Debt: $23B, litigation payouts, capex, R&D, buybacks, and acquisitions all compete for the same cash
Is Cooper's liquidity adequate for next year?
The provided data supports a cautiously adequate view because Fiscal Year 2026 Free Cash Flow Guidance: Approximately $650M excludes litigation payouts and Q2 2026 free cash flow was positive However, maturities, covenants, and full working-capital detail were not provided
What does net debt mean for COO investors?
Net Debt: $23B means Cooper carries meaningful leverage after cash offsets Investors should compare that burden with free cash flow, interest expense, litigation cash needs, and reinvestment plans rather than judging financial health from revenue growth alone
Are Cooper's reinvestment needs financially manageable?
Reinvestment appears manageable but not effortless The company funded Capital Expenditures: $864M and still produced Q2 2026 Free Cash Flow: $964M, while also supporting R&D, product launches, selective acquisitions, and repurchases under a leveraged balance sheet